ClinicalTrials.gg
CompletedNCT07426796Updated Sep 3, 2026

Comparison of Posterior QLB and QIPB in Pediatric Undescended Testis Surgery.

An interventional study of Ultrasound-guided Posterior Quadratus Lumborum Block. and Ultrasound-guided Quadroiliac Plane Block in Postoperative Pain and Cryptorchidism, sponsored by Medipol University. Completed at 1 site in Turkey (Türkiye). Open to male participants aged 1 Year to 7 Years. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Medipol University · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
1 Year to 7 Years
Sex
Male
01

Study summary

This randomized, double-blind study compares the postoperative analgesic efficacy of ultrasound-guided Posterior Quadratus Lumborum Block (QLB) versus Quadroiliac Plane Block (QIPB) in pediatric patients aged 1-7 years undergoing unilateral undescended testis surgery.

Read the detailed description

Lower abdominal surgeries, such as undescended testis repair (orchiopexy), are common in pediatric patients and can cause significant postoperative pain. While Posterior Quadratus Lumborum Block (QLB) is a known technique for somatic and visceral analgesia, the Quadroiliac Plane Block (QIPB) is a newer approach targeting the fascial plane posterior to the iliac bone.

In this prospective, randomized, controlled trial, 70 pediatric patients (ASA I-II, aged 1-7 years) will be randomly assigned to receive either a Posterior QLB or a QIPB under general anesthesia. Both blocks will be performed using ultrasound guidance with 0.5 mL/kg of 0.25% bupivacaine.

The study aims to evaluate and compare the analgesic efficacy of these two techniques. Postoperative pain will be assessed using the FLACC scale. Secondary objectives include comparing the time to first rescue analgesic, total analgesic consumption, and incidence of complications.

02

Conditions studied

  • Postoperative Pain
  • Cryptorchidism
03

In context

Pain, Postoperative

5,640 studies on the registry are indexed under Pain, Postoperative; 1,230 are open to participants now.

This study's enrollment of 70 is close to the median of 75 across 4,821 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

Medipol University is the lead sponsor of 326 studies on the registry; 88 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 7 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male pediatric patients aged 1-7 years.
  • I or II.
  • Scheduled for unilateral undescended testis surgery.
  • Written obtained.

Exclusion criteria

Exclusion Criteria:

  • History of neurological deficit or developmental delay.
  • Bleeding diathesis or known coagulopathy.
  • History of allergy to local anesthetics.
  • Infection or skin lesion at the block injection site.
  • Congenital spinal anomaly.
  • Mental retardation or psychiatric history.
  • Liver or kidney dysfunction.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Posterior QLB Group

    Patients will be placed in the lateral decubitus position. Under ultrasound guidance, the probe will be placed at the posterior axillary line. The needle will be advanced to the posterior fascial plane of the quadratus lumborum muscle. A total of 0.5 mL/kg of 0.25% Bupivacaine will be injected

    Procedure: Ultrasound-guided Posterior Quadratus Lumborum Block.

  • Experimental
    QIPB Group

    Patients will be placed in the lateral decubitus position. Under ultrasound guidance, the probe will be placed at the level of the iliac crest. The needle will be targeted to the plane where the quadratus lumborum muscle attaches to the iliac bone. A total of 0.5 mL/kg of 0.25% Bupivacaine will be injected.

    Procedure: Ultrasound-guided Quadroiliac Plane Block

Interventions

  • ProcedureUltrasound-guided Posterior Quadratus Lumborum Block.

    Patients will be placed in the lateral decubitus position. Under ultrasound guidance, the probe will be placed at the posterior axillary line. The needle will be advanced to the posterior fascial plane of the quadratus lumborum muscle. A total of 0.5 mL/kg of 0.25% Bupivacaine will be injected.

  • ProcedureUltrasound-guided Quadroiliac Plane Block

    Patients will be placed in the lateral decubitus position. Under ultrasound guidance, the probe will be placed at the level of the iliac crest. The needle will be targeted to the plane where the quadratus lumborum muscle attaches to the iliac bone. A total of 0.5 mL/kg of 0.25% Bupivacaine will be injected

06

What researchers measure

Primary outcomes

  1. Postoperative Pain Score (FLACC) at 12 Hours

    Pain severity assessed using the Face, Legs, Activity, Cry, Consolability (FLACC) scale. The total score ranges from 0 to 10, where higher scores indicate worse pain.

    Time frame: 12 hours post-surgery.

Secondary outcomes

  1. Time to First Rescue Analgesic Request.

    Time in minutes from surgery completion to the first dose of rescue analgesia.

    Time frame: Up to 24 hours.

  2. Total Postoperative Analgesic Consumption

    Cumulative amount of rescue analgesics consumed (mg).

    Time frame: 24 hours post-surgery.

  3. Incidence of Postoperative Complications.

    Assessment of complications such as urinary retention, motor block, hematoma, or ecchymosis at the injection site.

    Time frame: Up to 24 hours.

  4. Postoperative Pain Scores (FLACC) at Other Time Points.

    Pain severity assessed using the Face, Legs, Activity, Cry, Consolability (FLACC) scale at 30 minutes, 1, 2, 4, 6, and 24 hours. The total score ranges from 0 to 10, where higher scores indicate worse pain.

    Time frame: 30 minutes, 1, 2, 4, 6, and 24 hours post-surgery.

07

Study locations

1 site
  • Istanbul Medipol University
    Istanbul, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07426796
Lead sponsor
Medipol University
Collaborators
Biruni University, Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
Responsible party
Burak Omur (assistant professor, Medipol University) — Principal investigator
First posted
Feb 23, 2026
Start date
Feb 16, 2026
Primary completion
Aug 17, 2026
Completion
Aug 27, 2026
Last update
Sep 3, 2026

Study contacts

Selçuk Alver
study chair · Biruni University
Volkan Özen
study chair · Prof. Dr. Cemil Tascioglu City Hospital, Istanbul.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion